• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Practical Matters: Topical atropine: An overused medication

March 1, 2005
Cynthia S. Cook, DVM, PhD, DACVO

Atropine is a strong parasympathetic blocking agent. When applied topically, it causes pupillary dilatation that may last several days. Topical atropine should be administered only when this degree of pupillary dilatation is desired, which is not often.

Atropine is a strong parasympathetic blocking agent. When applied topically, it causes pupillary dilatation that may last several days. Topical atropine should be administered only when this degree of pupillary dilatation is desired, which is not often.

Contrary to what many of us were taught in veterinary school, atropine appears to be of little value in pain relief in the treatment of most superficial corneal ulcers. Intraocular inflammation (uveitis) may be associated with painful ciliary spasm, clinically identified because of the associated miosis. Most superficial corneal ulcers have minimal secondary uveitis and do not exhibit miosis. The mydriasis and cycloplegia caused by atropine would not be expected to provide pain relief in the absence of miosis. Pain associated with superficial corneal ulcers is caused by direct stimulation of damaged and exposed corneal nerves rather than by secondary uveitis. Atropine has no topical anesthetic effect, yet it is often administered for pain relief in patients with superficial corneal ulcers. Disadvantages of topical atropine include prolonged pupillary dilatation, photophobia, an inability to assess direct pupillary light responses, and the potential to increase intraocular pressure, particularly if the pressure is already elevated.

Good alternatives to topical atropine are available and should be selected based on the effect desired. Tropicamide 1% causes a similar parasympathetic blockade that only lasts three or four hours. It is not as strong a mydriatic and must be applied more often than atropine to maintain pupillary dilatation. Although also not a strong mydriatic, phenylephrine 2.5% is a sympathomimetic agent that when used in combination with tropicamide can dilate the pupils for diagnostic or therapeutic purposes. In cases of pupillary adhesions (posterior synechia), mechanically breaking the adhesions by pharmacologic means is often ineffective. Tropicamide-induced mydriasis encourages a mobile pupil because its effect wears off more quickly than atropine's effect. This is advantageous in eyes with inflammation, as adhesions can reform with the pupil fixed in a dilated position.

Advertisement

In summary, I use topical atropine rarely and often see it used inappropriately, occasionally to deleterious effect. Consider using tropicamide instead.

Cynthia S. Cook, DVM, PhD, DACVO

Veterinary Vision Animal Eye Specialists

219 N. Amphlett Blvd.

San Mateo, CA 94401

Related Content:

Ophthalmology
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens
American College of Veterinary Ophthalmologists to offer service and working animals free eye exams
American College of Veterinary Ophthalmologists to offer service and working animals free eye exams
Senior penguins receive revolutionary cataract surgery
Senior penguins receive revolutionary cataract surgery

Advertisement

Latest News

CE: Why tapeworms matter

Freshpet and Petco partner launch fresh pet food subscription

AAHA Con heads to San Diego

VHMA announces latest class of CVPMs

View More Latest News
Advertisement